uniQure N.V.
http://www.uniqure.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From uniQure N.V.
No AdComm Puts Sarepta On Path To Blockbuster Success With Duchenne Gene Therapy
The US FDA’s waiving of an advisory committee is another promising signal that Sarepta's Duchenne gene therapy SRP-9001 could be approved on 29 May and set it up to become a bigger earner than Novartis’s Zolgensma.
CSL/UniQure’s Hemgenix To Enter Uncertain EU Market After Regulatory Nod
The firms’ one-time hemophilia B gene therapy has been approved in the EU just months after a US nod, but concerns remain about its prospects on a market that has seen several setbacks for other gene therapies.
Deal Watch: BMS Returning IL-12 Candidate To Frequent Partner Dragonfly
The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.
Bountiful Approvals May Be Ahead As FDA Starts 2023 With Almost 60 Novel Agents Under Review
The upcoming year could see a rebound approvals if the bigger-than-usual queue of novel agents with 2023 user fee goal dates pans out.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Amsterdam Molecular Therapeutics (AMT)
- Corlieve Therapeutics SAS
- InoCard GmbH
- uniQure Germany GmbH
- uniQure U.S.A.
- uniQure The Netherlands
- uniQure Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice